Skip to content

Study · Non-randomized trial · n = 48 · 2011

3 results

[Efficacy of prolonged therapy of vascular dementia].

The source lists no authors.

Klinicheskaia meditsina1 Jan 2011Cited by 1 (Europe PMC)

PMID22242270 (opens in a new tab)PepBankPUB-22242270
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In vascular dementia patients, long-term cerebrolysin therapy improved cognitive function at early and late treatment stages regardless of disease severity.

    In plain wordsIn vascular dementia patients, cerebrolysin improved thinking abilities during early and late treatment stages compared with their initial condition.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive function
    Study

    n = 48

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    The long-term therapy with cerebrolysin was shown to be safe and highly efficacious as indicated by the improvement of cognitive and motor functions both at early and late stages of the treatment regardless of the severity of the disease.
    2 context sentences
    Summary · context
    This open study was designed to assess efficacy and safety of long-term therapy with cerebrolysin in 48 patients aged 59-77 years with mild and moderately severe vascular dementia.
    Summary · context
    The slowdown in the progress of this condition during the 3-year treatment period was evaluated.
  2. 02HumanNon-randomized trialEfficacy outcome

    In vascular dementia patients, long-term cerebrolysin therapy improved motor function at early and late treatment stages regardless of disease severity.

    In plain wordsIn vascular dementia patients, cerebrolysin improved movement during early and late treatment stages compared with their initial condition.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMotor function
    Study

    n = 48

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    The long-term therapy with cerebrolysin was shown to be safe and highly efficacious as indicated by the improvement of cognitive and motor functions both at early and late stages of the treatment regardless of the severity of the disease.
    2 context sentences
    Summary · context
    This open study was designed to assess efficacy and safety of long-term therapy with cerebrolysin in 48 patients aged 59-77 years with mild and moderately severe vascular dementia.
    Summary · context
    The slowdown in the progress of this condition during the 3-year treatment period was evaluated.
  3. 03HumanNon-randomized trialSafety outcome

    In vascular dementia patients, the study described long-term cerebrolysin therapy as safe without reporting specific adverse event results.

    In plain wordsIn vascular dementia patients, the study described cerebrolysin treatment as safe but gave no specific side effect results.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedOverall safety
    Study

    n = 48

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    The long-term therapy with cerebrolysin was shown to be safe and highly efficacious as indicated by the improvement of cognitive and motor functions both at early and late stages of the treatment regardless of the severity of the disease.
    2 context sentences
    Summary · context
    This open study was designed to assess efficacy and safety of long-term therapy with cerebrolysin in 48 patients aged 59-77 years with mild and moderately severe vascular dementia.
    Summary · context
    The slowdown in the progress of this condition during the 3-year treatment period was evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.